We further hypothesize that a combination of partial FXR activation[12] and inhibition of leukotriene A4 hydrolase (LTA4H) can efficiently counteract NAFLD/NASH. The gene discussed is LTA4H; the disease is metabolic dysfunction-associated steatotic liver disease.